Catalyst Pharma chair disposes 4.17M shares in $31.50 deal
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Patrick J. McEnany, chairman of Catalyst Pharmaceuticals, reported the disposition of 4,171,559 shares of common stock at $31.50 per share in connection with the acquisition of Catalyst by Angelini Pharma S.p.A., and this Form 4 shows 0 shares of common stock held directly afterward.
The reported restricted stock units and stock options covering additional shares were cancelled at merger closing and converted into rights to receive cash payments based on a $31.50 per-share value, with each award vesting in full at consummation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 740,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 400,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 270,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 272,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 73,810 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 43,591 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 34,921 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 3,534 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 3,552 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 10,540 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 4,171,559 | $31.50 | $131.40M |
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Key Terms
restricted stock unit financial
stock option financial
Merger financial
Angelini Pharma S.p.A. financial
cash payment financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Patrick J. McEnany report for Catalyst Pharmaceuticals (CPRX)?
What happened to Patrick J. McEnany’s RSUs in the Catalyst Pharmaceuticals (CPRX) merger?
How were Patrick J. McEnany’s Catalyst Pharmaceuticals (CPRX) stock options treated in the Angelini Pharma acquisition?
Were Patrick J. McEnany’s Catalyst (CPRX) equity awards vested at the time of the merger?
Was Patrick J. McEnany’s Form 4 for Catalyst Pharmaceuticals (CPRX) filed under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.